Lyra Therapeutics, Inc. (LYRA)
| Market Cap | 12.81M |
| Revenue (ttm) | 1.47M |
| Net Income (ttm) | -97.61M |
| Shares Out | 65.46M |
| EPS (ttm) | -1.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,249,813 |
| Open | 0.170 |
| Previous Close | 0.168 |
| Day's Range | 0.165 - 0.209 |
| 52-Week Range | 0.163 - 6.790 |
| Beta | -0.04 |
| Analysts | Buy |
| Price Target | 4.50 (+2,199.44%) |
| Earnings Date | Nov 12, 2024 |
About LYRA
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase... [Read more]
Financial Performance
In 2023, Lyra Therapeutics's revenue was $1.56 million, an increase of 14.31% compared to the previous year's $1.36 million. Losses were -$62.68 million, 13.4% more than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for LYRA stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 2,199.44% from the latest price.
News
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammator...
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company deve...
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory ...
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned –
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by implementing a...
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“...
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
-- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May -- -- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in...
3 'Buy-Rated' Biotech Stocks Under $10
Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presente...
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal impl...
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: L...
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory ...
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic rhino...
Lyra Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chroni...
Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer
WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the loc...
Lyra Therapeutics: Hold For Phase 3 Topline
Lyra Therapeutics has two product candidates in clinical trials for Chronic rhinosinusitis (CRS) patients. Both candidates, LYR-210 and LYR-220, show promising efficacy data, with LYR-210 in phase 3 t...
Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity
Lyra Therapeutics' LYR-220 shows promise in addressing chronic rhinosinusitis, targeting a patient demographic that doesn't respond to current treatments. The company maintains a stable balance sheet ...
Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
Study demonstrates statistically significant and clinically relevant improvements in 3 Cardinal Symptoms and SNOT-22 scores at 24 weeks
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory th...
Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in the Coming Weeks, with Data Expected in 1H 2024 -- -- Initial Topline Re...
Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference
WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patien...
Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment
Lyra is a small company founded by Bob Langer of MIT. The company has solid Phase 2 data in chronic rhinosinusitis, and Phase 3 data drop is early next year. Lyra has a decent cash runway and looks in...
Lyra Therapeutics to Present at Jefferies Healthcare Conference
WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patien...
Lyra Therapeutics Announces Closing of $50.0 Million Private Placement
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the loc...
Lyra Therapeutics Announces $50.0 Million Private Placement
WATERTOWN, Mass., May 26, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the loca...
Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment, with Data Expected in 1H 2024 -- -- Data from BEACON Phase 2 Trial of LYR-...